<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3383">
  <stage>Registered</stage>
  <submitdate>30/11/2011</submitdate>
  <approvaldate>30/11/2011</approvaldate>
  <nctid>NCT01483742</nctid>
  <trial_identification>
    <studytitle>A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis</studytitle>
    <scientifictitle>A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR and RO5024048 in Different Combinations in Null Responder or Treatment Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-004129-28</secondaryid>
    <secondaryid>NP27946</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - RO5024048
Treatment: drugs - danoprevir
Treatment: drugs - peginterferon alfa-2a [Pegasys]
Treatment: drugs - ribavirin
Treatment: drugs - ritonavir

Experimental: Combination without RO5024048 - Ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients

Experimental: Combination with RO5024048 - RO5024048 added to the combination treatment (ritonavir-boosted danoprevir in combination with Pegasys [peginterferon alfa-2a] and ribavirin) in prior null responder patients


Treatment: drugs: RO5024048
1000 mg orally bid, 24 weeks

Treatment: drugs: danoprevir
100 mg orally bid, 24 weeks

Treatment: drugs: peginterferon alfa-2a [Pegasys]
180 mcg weekly, 24 weeks

Treatment: drugs: ribavirin
1000-1200 mg/kg/day orally in two divided doses, 24 weeks

Treatment: drugs: ritonavir
100 mg orally bid, 24 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>48 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics (PK): Area under the concentration-time curve (AUC)</outcome>
      <timepoint>Intensive PK sample collection during initial 2 week dosing period, followed by routine sampling during treatment up to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Antiviral activity: Hepatitis C virus (HCV) RNA levels assessed by Roche COBAS Taqman HCV Test</outcome>
      <timepoint>48 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Emergence of viral resistance: HCV RNA gene sequence variations</outcome>
      <timepoint>From baseline to Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virologic response: HCV RNA levels</outcome>
      <timepoint>approximately 1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult patients, 18 to 65 years of age inclusive

          -  Chronic hepatitis C, genotype 1 or 4

          -  Cohort 1: Treatment-naïve for hepatitis C

          -  Cohort 2: Prior null responder to treatment with approved doses of pegylated
             interferon plus ribavirin

          -  Liver biopsy confirming cirrhosis

          -  Compensated cirrhosis (Child-Pugh A)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or lactating women or male partners of women who are pregnant

          -  History or presence of decompensated liver disease (ascites, hepatic encephalopathy,
             hepatocellular carcinoma, or bleeding esophageal varices)

          -  Cohort 2: Patients who discontinued previous pegylated interferon plus ribavirin
             treatment due to reasons other than null response

          -  History of clinically significant cardiovascular or cerebrovascular disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>43</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital> - Fitzroy</hospital>
    <hospital> - Melbourne</hospital>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3124 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chorzów</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Myslowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open-label, parallel cohort study will evaluate the safety, pharmacokinetics and
      antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon
      alfa-2a) and ribavirin in treatment-naïve patients, and with RO5024048 added to the
      combination treatment in prior null responder patients with chronic hepatitis C genotype 1 or
      4 and compensated cirrhosis. All patients will receive danoprevir 100 mg orally twice daily
      (bid) , ritonavir 100 mg orally bid, Pegasys 180 mcg subcutaneously weekly and ribavirin
      1000-1200 mg/kg/day orally. Prior non-responders will receive RO5024048 1000 mg orally bid
      additionally. Anticipated time on study treatment is 24 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01483742</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>